Concepedia

Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir

Kristina M. Brooks, José Castillo‐Mancilla, Mary Morrow, Samantha MaWhinney, Joshua Blum, David Wyles, Sarah E. Rowan, Mustafa E. Ibrahim, Jia‐Hua Zheng, B. D. Johnson,

Journal of Antimicrobial Chemotherapy · 2020 · 10 citations · 38 references

DOIFull text

Open access

Abstract

Ledipasvir/sofosbuvir did not significantly increase plasma tenofovir or intracellular TFV-DP in PBMCs with TAF. These findings provide reassurance that the combination of TAF, boosted PIs and ledipasvir/sofosbuvir is safe in HIV/HCV-coinfected populations.

References

38

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 48.8K citations · Full text

, , +10

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris, Robert J. Taylor, Brenda L. Minor et al. · Journal of Biomedical Informatics · 2019 · 22.2K citations · Full text

, , +13

EASL Recommendations on Treatment of Hepatitis C 2018

Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo et al. · Journal of Hepatology · 2018 · 2.8K citations

, , +4

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 593 citations

, , +10